Rapid Micro Biosystems (NASDAQ:RPID) Major Shareholder Longitude Capital Partners Ii, Sells 49,000 Shares

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) major shareholder Longitude Capital Partners Ii, sold 49,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $3.88, for a total value of $190,120.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Longitude Capital Partners Ii, also recently made the following trade(s):

• On Monday, February 2nd, Longitude Capital Partners Ii, sold 27,500 shares of Rapid Micro Biosystems stock. The stock was sold at an average price of $4.25, for a total value of $116,875.00.
• On Friday, January 30th, Longitude Capital Partners Ii, sold 46,000 shares of Rapid Micro Biosystems stock. The shares were sold at an average price of $4.54, for a total value of $208,840.00.
• On Friday, January 23rd, Longitude Capital Partners Ii, sold 7,739 shares of Rapid Micro Biosystems stock. The shares were sold at an average price of $4.06, for a total transaction of $31,420.34.

Rapid Micro Biosystems Stock Up 5.2%

NASDAQ:RPID opened at $3.87 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 4.23 and a quick ratio of 2.95. The firm’s 50-day moving average price is $3.67 and its 200-day moving average price is $3.40. The company has a market capitalization of $171.52 million, a PE ratio of -3.83 and a beta of 1.38. Rapid Micro Biosystems, Inc. has a 1-year low of $1.86 and a 1-year high of $4.94.

Rapid Micro Biosystems (NASDAQ:RPID) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). The business had revenue of $7.84 million for the quarter, compared to analyst estimates of $7.60 million. Rapid Micro Biosystems had a negative net margin of 145.11% and a negative return on equity of 73.90%. On average, equities analysts predict that Rapid Micro Biosystems, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Trading of Rapid Micro Biosystems

Several institutional investors and hedge funds have recently modified their holdings of the company. Evernest Financial Advisors LLC boosted its holdings in Rapid Micro Biosystems by 355.1% in the 3rd quarter. Evernest Financial Advisors LLC now owns 200,234 shares of the company’s stock worth $669,000 after buying an additional 156,234 shares during the period. Vanguard Group Inc. boosted its stake in shares of Rapid Micro Biosystems by 6.7% in the third quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock worth $3,223,000 after acquiring an additional 60,655 shares during the period. XTX Topco Ltd purchased a new stake in shares of Rapid Micro Biosystems during the second quarter worth about $144,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Rapid Micro Biosystems during the 4th quarter valued at approximately $72,000. Finally, Dimensional Fund Advisors LP raised its stake in Rapid Micro Biosystems by 37.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company’s stock valued at $186,000 after purchasing an additional 15,255 shares during the period. 52.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on RPID shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. Wall Street Zen cut Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.